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Phase I Trial of Nanoparticle Albumin-Bound Paclitaxel in
Combination with Gemcitabine in Patients with Thoracic
Malignancies
Thomas E. Stinchcombe, MD,*† Mark A. Socinski, MD,* Carrie B. Lee, MD,*
D. Neil Hayes, MD, MPH,* Dominic T. Moore, MPH,‡ Richard M. Goldberg, MD,†§
and E. Claire Dees, MD†
Background: Nab-paclitaxel has a different toxicity profile than
solvent-based paclitaxel including a lower rate of severe neutrope-
nia. This trial was designed to determine the maximum tolerated
dose and dose limiting toxicities (DLT) of nab-paclitaxel in combi-
nation with gemcitabine.
Methods: Patients were required to have a performance status of 0
to 1, three prior cytotoxic chemotherapy regimens, and preserved
renal, hepatic, and bone marrow function. Patients received gemcit-
abine 1000 mg/m2 on days 1, 8 in all cohorts, and nab-paclitaxel at
doses of 260, 300, 340 mg/m2 every 21 days depending on the
treatment cohort (1 cycle  21 days). DLT were assessed after the
first cycle, and doses were escalated in cohorts of 3 to 6 patients.
Results: Eighteen patients were consented and 15 patients are
evaluable [median age 62 years (range, 35–75); median number of
prior treatments 3 (range, 1–4); tumor types: non-small cell lung
cancer (NSCLC) (n  8), small cell lung cancer (SCLC) (n  6),
and esophageal cancer (n  1)]. At a nab-paclitaxel dose of 300
mg/m2, 1 of 6 pts experienced a DLT (omission of day 8 gemcit-
abine due to absolute neutrophil count 500), and at an nab-
paclitaxel dose of 340 mg/m2 2 of 3 patients experienced a DLT (1
pt grade 3 rash and pruritus; 1 pt grade 3 fatigue and anorexia).
Responses were observed in NSCLC and SCLC.
Conclusions: The maximum tolerated dose of nab-paclitaxel is 300
mg/m2 in combination with gemcitabine 1000 mg/m2 on days 1, 8
every 21 days. This combination demonstrated activity in previously
treated NSCLC and SCLC patients.
Key Words: Abraxane, Non-small cell lung cancer, Small cell
cancer, Esophageal cancer, ABI-007, Taxane.
(J Thorac Oncol. 2008;3: 521–526)
Paclitaxel has demonstrated significant activity, either as asingle agent or in combination with other chemotherapeu-
tic or biologic agents in the treatment of breast, ovarian, lung,
and squamous cell cancers of the head and neck. However,
paclitaxel has several burdensome toxicities including hyper-
sensitivity reactions, sensory neuropathy, myelosuppression,
and mild nausea.1 Nanoparticle albumin-bound paclitaxel
(nab-paclitaxel, ABI-007, Abraxane), a solvent-free formula-
tion of paclitaxel, has recently been approved by the United
States Food and Drug Administration for use in treatment of
metastatic breast cancer, and has some practical advantages
over standard formulation paclitaxel including a lack of
hypersensitivity reactions and shorter infusion time. A phase
III clinical trial compared paclitaxel with nab-paclitaxel in
patients with metastatic breast cancer.2 Patients who were
treated with nab-paclitaxel experienced a significantly higher
response rate, and time to tumor progression in comparison to
paclitaxel. Patients who were treated with nab-paclitaxel
experienced a significantly lower rate of grade 4 neutropenia,
but had a higher rate of grade 3 sensory neuropathy in
comparison to patients treated with paclitaxel. Phase II trials
with single agent nab-paclitaxel and in combination with
carboplatin have revealed significant activity in non-small
cell lung cancer (NSCLC).3–6 A phase III trial comparing
carboplatin and paclitaxel versus carboplatin and nab-pacli-
taxel has been initiated in patients with advanced NSCLC.
Standard first-line chemotherapy for advanced NSCLC is
a platinum-based doublet therapy; however, nonplatinum dou-
blets are an acceptable alternative.7 Gemcitabine and paclitaxel
is a nonplatinum combination that is used to treat advanced
non-small cell lung cancer8,9 and metastatic breast cancer.10
However, there are significant differences in the standard doses
and toxicities between nab-paclitaxel and paclitaxel, and thus the
potential for additive toxicity with the combination of nab-
paclitaxel and gemcitabine. Therefore, we performed a phase I
trial to determine the maximum tolerated dose (MTD) and the
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dose limiting toxicities (DLT) of nab-paclitaxel in combination
with a standard dose and schedule of gemcitabine.8,9
PATIENTS AND METHODS
Patients were required to have a cytologically or histo-
logically confirmed advanced solid tumor, and a preserved
functional status, organ function, a life expectancy of 8
weeks, and be able to provide informed consent. Patients who
had received 3 lines of cytotoxic chemotherapy for meta-
static disease or were considered heavily pretreated (as de-
fined in Table 1) were excluded; however, there was no
exclusion criterion related to prior taxane therapy. Patients
were required to meet all the inclusion and exclusion criteria
(Table 1). Toxicity was assessed after each cycle using the
National Cancer Institute Common Terminology Criteria Ad-
verse Events version 3.0. Dose limiting toxicities were deter-
mined after the first cycle, and were defined as on Table 1.
Patients were evaluated with weekly complete blood cell
count; liver function tests [aspartate aminotransferase, ala-
nine transaminase, alkaline phosphatase, and total bilirubin]
and serum creatinine were evaluated before each cycle of
chemotherapy. Efficacy was determined using the Response
Evaluation Criteria in Solid Tumors.11 Patients were assessed
for response after every two cycles (6 weeks). All patients
were required to sign informed consent before any study
procedures being performed. This trial was reviewed by the
protocol review committee of Lineberger Comprehensive
Cancer Center and the Institutional Review Board of the
University of North Carolina.
Study Design
This was a phase I single-center trial, and the primary
objective was to determine the DLT and the MTD of nab-
paclitaxel in combination with gemcitabine. The secondary ob-
jectives were to evaluate the efficacy and toxicity of the com-
bination of nab-paclitaxel and gemcitabine. The trial used a
standard 3-patient cohort dose escalation design. Three patients
were treated at the initial dose level, and if no first cycle DLTs
were observed, three additional patients were treated at the next
dose level. If one of the three initial patients experienced a DLT
at any given dose level, three additional patients were treated at
the same dose level. If a DLT occurred in at least two patients at
any dose level, dose escalation was halted, and the next three
patients were enrolled at the next lower dose level. The MTD
and the recommended treatment dose for phase II trials was
defined as the highest dose levels that fewer than two of six
patients experienced DLT in cycle one. The cohort at the MTD
and recommended dose for phase II trials could be expanded to
obtain additional efficacy and toxicity information about this
dose level. The toxicities observed in the patients on the ex-
panded cohort were not included in the determination of the
DLT or MTD.
Study Treatment
Patients received gemcitabine 1000 mg/m2 on days 1, 8
and nab-paclitaxel on day 1 every 21 days, and the dose of
nab-paclitaxel depended on the patient’s cohort. Patients
received gemcitabine infused over 30 minutes, followed by a
30-minute infusion of nab-paclitaxel on day 1, and gemcit-
abine was infused over 30 minutes on day 8. Dose adjust-
ments for the day 8 gemcitabine were as follows: 100% of the
dose if absolute neutrophil count (ANC) was 1000  106/l
and platelet count 100,000  106/l, and 75% of the dose if
the ANC 500–999  106/l or platelet count 50,000 to
99,000  106/l. The day 8 dose of gemcitabine was not
TABLE 1. Inclusion and Exclusion Criteria and
Dose-Limiting Toxicities
Inclusion criteria
1. Histologically or cytologically documented solid tumors
2. Measurable disease by RECIST
3. Patients must have progressed on standard therapy, not be a
candidate for standard therapy, or have a disease or disease status
for which there is no defined standard therapy
4. Age 18 yr
5. Eastern Cooperative Oncology Group (ECOG) functional status of
0–2
6. Adequate organ function defined as:
Renal: serum creatinine 1.5  ULN or Cockcraft calculated
creatinine clearance of 60 ml/min
Hepatic: transaminases 2.5  ULN and total bilirubin in normal
range
Bone marrow: ANC 1.5  106/l, platelet count 100,000  106/l
7. Life expectancy of at least 8 wk
Exclusion criteria
1. Previous anaphylactic reaction or severe allergic reaction to
paclitaxel and/or docetaxel
2. Previous anaphylactic reaction or severe allergic reaction to
gemcitabine
3. Symptomatic brain metastases
4. Inability to sign informed consent
5. Pregnant or lactating women
6. Active infectious process that will require treatment with antibiotics
for greater than 4 wk
7. Uncontrolled congestive heart failure
8. Symptomatic coronary artery disease or heart block
9. Myocardial infarction within the last 3 months
10. Chemotherapy, radiation therapy or any other treatment for
malignancy within the last 3 wk
11. Grade 2 peripheral neuropathy at baseline assessment from any
cause
12. Irradiation of 25% of bone marrow
13. Prior exposure to nitrosureas
14. Prior exposure to 6 cycles of alkylating agents
15. Prior exposure to 2 cycles of mitomycin
16. Treatment with 3 previous lines of cytotoxic therapy for
metastatic disease
Dose limiting toxicities based on first cycle toxicities*
1. Grade 3 nonhematological toxicity
2. Grade 4 thrombocytopenia or anemia
3. Grade 4 neutropenia lasting 7 days
4. Dose delay of initiating the second cycle of 2 wk
5. Day 8 gemcitabine being held related to ANC 500  106/l or
platelet count 50,000  106/L
ULN, upper limit of normal; ANC, absolute neutrophil count; RECIST, Response
Evaluation Criteria in Solid Tumors.
*Based on National Cancer Institute Common Terminology Criteria for Adverse
Events (NCI CTCAE) version 3.0.
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administered if the ANC was 500  106/l or the platelet
count 50,000  106/l. The doses of nab-paclitaxel and
gemcitabine were calculated using the patient’s body surface
area, with doses capped at a maximum body surface area of
2.0. Patients were treated until disease progression, unaccept-
able toxicity, two cycles after maximal response or a maxi-
mum of six cycles at the discretion of the treating physician.
Patients received antiemetic therapy with dexametha-
sone before each treatment with nab-paclitaxel and gemcit-
abine on day 1 and dexamethasone alone before treatment
with single agent gemcitabine on day 8. No additional pre-
medications for hypersensitivity reactions were given. Nab-
paclitaxel (Abraxane) and gemcitabine (Gemzar) were sup-
plied by the manufacturers. The use of growth colony
stimulating factors was prohibited during the first cycle, and
could be used after the first cycle if indicated following the
American Society of Clinical Oncology guidelines.12 The use
of erythropoietin stimulating agents was permitted and based
on the American Society of Clinical Oncology guidelines
available at the time trial was performed.13
RESULTS
Eighteen patients were consented for this trial, and 15
patients are considered evaluable. Three patients are noneva-
luable for the following reasons: progressive disease prior to
initiating protocol therapy (n  1), withdrawal of consent
after cycle 1 day 1 therapy (n  1), and inability to meet
screening laboratory eligibility criteria (n  1). The demo-
graphics of the evaluable 15 patients are presented in Table 2.
The majority of the patients were: white (n 14), male (n 8)
and had non-small cell or small cell lung cancer (n 14). The
median number of prior therapies was 3.
Determination of the Maximum Tolerated Dose
No DLT were observed in the first cohort (nab-pacli-
taxel 260 mg/m2 every 21 days). At the second-dose level
(nab-paclitaxel 300 mg/m2 every 21 days), one of the 6
patients experienced DLT (omission of day 8 gemcitabine
due to ANC 500  106/l). In the third dose cohort (340
mg/m2 every 21 days), 2 of the first 3 patients experienced a
DLT (grade 3 fatigue/asthenia and grade 3 anorexia in one
patient, grade 3 rash and grade 3 pruritis in one patient). The
MTD and recommended dose for phase II trials is nab-
paclitaxel is 300 mg/m2 on day 1 in combination with
gemcitabine 1000 mg/m2 on days 1, 8, every 21 days.
Toxicities
The hematological toxicities for all the cycles are sum-
marized in Table 3. The rate of severe hematological toxicity
was low with grade 4 neutropenia observed in one cycle, and
one episode of febrile neutropenia. Growth colony stimulat-
ing factors supportive therapy was not used during any of the
cycles. Grade 3 anemia and grade 3 thrombocytopenia were
each observed in one cycle. Two patients were treated with
erythropoietin stimulating agents for a total of 4 cycles, and
one patient had transfusion of 2 units packed red blood cells.
The main nonhematological toxicities consisted of sensory
neuropathy, nausea, vomiting, fatigue, and alopecia. The
nonhematological toxicities for all patients are summarized in
Table 4. One patient in the expanded cohort developed grade
3 pneumonitis, which was attributed to the gemcitabine. The
patient was treated with supplemental oxygen and corticoste-
roids with improvement of his dyspnea and oxygenation, and
did not continue treatment due to evidence of disease pro-
gression and toxicity. Two patients discontinued therapy due
to treatment related toxicity: one patient experienced grade 3
fatigue/asthenia and grade 3 anorexia after cycle 1 of nab-
paclitaxel at a dose of 340 mg/m2 and while eligible for
further therapy after a dose reduction, elected not to continue
and one patient experienced grade 3 sensory neuropathy
which did not resolve after a 2 week treatment delay. This
patient had underlying diabetes and had previously received
TABLE 2. Patient Characteristics at Baseline
Characteristic No.
Sample size 15
Median age (range) in years 62 (35–75)
ECOG performance status
0 6
1 8
2 1
Gender
Male 8
Female 7
Race
White 14
Black 1
Median number of previous cytotoxic therapies 3
Malignancy
Non-small cell lung cancer 8
Small cell lung cancer 6
Esophageal cancer 1
ECOG, Eastern Cooperative Oncology Group.
TABLE 3. Treatment-Related Hematological Toxicitya
Nab-Paclitaxel
(mg/m2)
No.
Patients
No.
Cycles
Neutropenia
Grade
Anemia
Grade
Thrombocytopenia
Grade
Febrile Neutropenia
Grade
1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4
260 3 17 7 1 2 0 5 1 0 0 3 0 0 0 0 0 1 0
300 9 39 11 7 9 1 15 3 1 0 9 0 1 0 0 0 0 0
340 3 3 0 2 3 0 2 1 0 0 1 0 0 0 0 0 0 0
a Worst grade of individual toxicity per cycle reported.
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paclitaxel: she received nab-paclitaxel 300 mg/m2 on cycle 1
and 260 mg/m2 on cycle 2. A second patient developed grade
3 sensory neuropathy after the second cycle, but did not have
a history of diabetes or previous paclitaxel therapy, and
discontinued therapy because of progressive disease.
Treatment Administration
A total of 59 cycles were administered and no patients
experienced any treatment delays related to myelosuppres-
sion. Patients received treatment with nab-paclitaxel at 3
different doses of nab-paclitaxel: 260 mg/m2 (17 cycles), 300
mg/m2 (39 cycles), and 340 mg/m2 (3 cycles). Four patients
underwent dose reduction of the nab-paclitaxel; the 3 patients
who experienced a DLT, and one patient who initiated ther-
apy at 340 mg/m2 had the nab-paclitaxel dose reduced when
it was determined that the dose level has an unacceptable rate
of toxicity. The day 8 gemcitabine was successfully admin-
istered on 58 of the 59 cycles. One patient had cycle 1 day 8
gemcitabine withheld due to neutropenia (and was considered
a DLT), and after dose adjustment of the nab-paclitaxel
received the day 8 gemcitabine on the second-cycle. On 7
cycles, the dose of the day 8 gemcitabine was adjusted from
1000 to 750 mg/m2. The dose intensity of the gemcitabine,
defined as the dose patients received divided by full dose
prescribed per protocol, was 98%, and for the day 8 gemcit-
abine was 95%.
Response
Thirteen of the 15 patients are evaluable for response;
2 patients discontinued therapy and are nonevaulable since
response was either not assessed or confirmed. The best
response per patient recorded from the start of treatment
until completion of protocol therapy that was confirmed on
repeating imaging 4 weeks is reported on Table 5. Partial
responses were seen among patients with small cell lung
cancer (SCLC) (n  3), and NSCLC (n  3); 4 patients
experienced stable disease [NSCLC (n  3) and esophageal
cancer (n  1)].
DISCUSSION
This phase I trial demonstrates that the MTD of nab-
paclitaxel was 300 mg/m2 on day 1 in combination with
gemcitabine 1000 mg/m2 on days 1, 8 on an every 21-day
schedule. This result is concordant with the findings from
other early phase trials of this agent alone or in combina-
tion.14–16 This dose of nab-paclitaxel did not seem to signif-
icantly compromise the treatment administration of the day 8
gemcitabine.
TABLE 4. Treatment Related Nonhematological Toxicitiesa
Nab-paclitaxel 260 mg/m2 300 mg/m2 340 mg/m2
No. patients 3 9 3
No. cycles 17 39 3
Grade 1 2 3 4 1 2 3 4 1 2 3 4
Sensory neuropathy 5 1 1 0 10 3 1 0 1 1 0 0
Nausea 0 1 0 0 11 4 0 0 2 1 0 0
Vomiting 0 0 0 0 5 2 0 0 0 0 0 0
Diarrhea 1 0 0 0 2 1 0 0 0 0 0 0
Mylagia 0 0 0 0 4 2 0 0 2 0 0 0
Arthralgias 0 0 0 0 2 1 0 0 1 1 0 0
Fatigue/asthenia 2 0 0 0 13 4 0 0 1 0 1 0
Feverb 0 0 0 0 4 0 0 0 2 0 0 0
Rashc 1 0 0 0 2 0 0 0 1 0 1 0
Pruritis 0 0 0 0 2 1 0 0 0 0 1 0
Peumonitis 0 0 0 0 0 0 1 0 0 0 0 0
Transaminitis 0 0 0 0 3 2 0 0 0 0 0 0
Electrolyted 0 0 0 0 1 0 0 0 0 0 1 0
Dehydration 0 0 0 0 2 1 0 0 0 1 0 0
Alopeciae
a Worst grade of individual toxicity per cycle reported.
b Fever in absence of neutropenia or identifiable infection.
c At nab-paclitaxel dose of 340 mg/m2 grade 3 rash consisted of diffuse erythema over 50% of the body associated with
grade 3 pruritis.
d At nab-paclitaxel dose of 300 mg/m2 grade 1 hyponatremia; at nab-paclitaxel dose of 340 mg/m2 grade 3 hyponatremia.
e All patients experienced grade 2 alopecia.
TABLE 5. Best Response as Assessed by RECIST11
Malignancy PR SD PD NEa
NSCLC 3 3 1 1
SCLC 3 0 2 1
Esophageal 0 1 0 0
RECIST, Response Evaluation Criteria in Solid Tumors; NSCLC, non-small cell
lung cancer; SCLC, small cell lung cancer; PR, partial response; SD, stable disease; PD,
progressive disease; NE, nonevaluable.
a Two patients were nonevaluable due to toxicity; one patient had grade 3 asthenia
and anorexia after the first cycle, one patient had grade 3 sensory neuropathy after the
second cycle and response was not confirmed.
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Two patients did develop grade 3 sensory neuropathy
on this trial; both after two cycles of treatment. The incidence
of grade 3 sensory neuropathy was higher with nab-paclitaxel
than paclitaxel in the phase III trial (10% versus 2%, respec-
tively; p  0.001).17 The incidence of sensory neuropathy is
known to increase significantly after four cycles of carbopla-
tin and paclitaxel,18 and the incidence of sensory neuropathy
related to nab-paclitaxel may be cumulative or dose depen-
dent. Given the variability in dose and number of cycles of
nab-paclitaxel received in previous trials, it is difficult to
make a definitive conclusion about the relationship between
these factors and the rate of grade 3 sensory neuropathy. In a
recent phase II dose escalation trial of carboplatin and nab-
paclitaxel, the incidence of sensory neuropathy appeared to
increase with increasing dose of nab-paclitaxel.5 In this trial,
all patients received carboplatin (area under the curve  6),
and patients received nab-paclitaxel 225, 260, 300, or 340
mg/m2 every 21 days depending on the cohort. The incidence
of grade 3 sensory neuropathy was 8%, 8%, 12%, and 24%,
respectively. Future clinical trials that investigate the dose
and schedule of nab-paclitaxel should include close monitor-
ing for this toxicity. Preliminary evidence indicates that
prolonging the infusion time of nab-paclitaxel from the stan-
dard 30 minutes to 2 hours may decrease the incidence of
grade 2 and 3 sensory neuropathy, presumably by decreasing
the peak plasma levels of nab-paclitaxel.19
This combination demonstrated significant activity: 6
patients experienced a partial response and 4 patients expe-
rienced stable disease in this previously treated population
(median number of previous cytotoxic therapies  3). How-
ever, these results should be interpreted with caution given
the small sample size and the fact that gemcitabine and
paclitaxel as single agents or in combination have demon-
strated significant activity in second-line therapy for NSCLC
and SCLC.20–23 Phase II trials in specific patient populations
will be required to assess the activity of this combination.
This combination may prove to be a nonplatinum alternative
regimen for patients with advanced NSCLC if phase II
studies confirm the preliminary indications of activity ob-
served in the previously treated patients enrolled in our trial.
The combination of gemcitabine and paclitaxel has
demonstrated similar efficacy and toxicity in comparison to
platinum-based doublet chemotherapy in advanced NSCLC
in two large phase III trials.8,9 The rate of neutropenia
observed with gemcitabine and paclitaxel in these trials has
been within acceptable limits. In the phase III trial by Kos-
midis et al., the percentage of patients experiencing grade 3
and 4 neutropenia on gemcitabine and paclitaxel treatment
arm (n  239) was 10% and 5%, respectively.9 In the phase
III trial by Treat et al., the percentage of patients on the
gemcitabine and paclitaxel treatment arm (n  328) experi-
encing grade 3 and 4 neutropenia and febrile neutropenia was
12% and 9%, respectively, and 3% and 1%, respectively. A
low incidence of grade 4 neutropenia (1 of 59 cycles) was
observed in this trial. However, the clinical benefit of the
substitution of nab-paclitaxel for paclitaxel in this combina-
tion to reduce the incidence of neutropenia, without a reduc-
tion of other toxicities or an improvement in efficacy, is
debatable. The low incidence on neutropenia may make the
combination of gemcitabine and nab-paclitaxel an attractive
chemotherapy combination to investigate with novel targeted
agents that may be associated with severe neutropenia. For
instance, the addition of bevacizumab to carboplatin and
paclitaxel in advanced NSCLC resulted in a statistically
significant increase in the rate of grade 4 neutropenia and
febrile neutropenia in comparison to standard carboplatin and
paclitaxel.24 Multitargeted tyrosine kinase inhibitors, such as
sunitinib or sorefenib, have demonstrated activity in NSCLC,
but may cause myelosuppression as well.25,26
One deficiency in this trial was that a pharmacokinetic
analysis was not performed. A phase I trial by Kroep et al.
investigated the schedule of gemcitabine 1000 mg/m2 on days
1, and 8 and escalating doses of paclitaxel (150 and 200
mg/m2) on day 1 every 21 days in 18 patients with advanced
NSCLC.27 Paclitaxel did not affect the pharmacokinetics of
gemcitabine, and nor did gemcitabine affect the pharmacoki-
netics of paclitaxel, and the conclusion of the trial was that no
drug-drug interactions were seen with this combination. A
phase I trial be Folgi et al. investigated for a potential
pharmacokinetic interaction between the two drugs with a
treatment schedule of paclitaxel 100 mg/m2 and escalating
doses of gemcitabine (1500, 1750, and 2000 mg/m2) on days
1, 8, and 15 every 28 days in 15 patients with advanced
NSCLC.28 This trial demonstrated no interaction between the
two drugs. A phase I trial by De Pas et al. investigated
escalating doses of gemcitabine (800–2000 mg/m2) and pac-
litaxel (60–100 mg/m2) on days 1, 8, and15 every 28 days in
35 patients with advanced NSCLC.29 No pharmacokinetic
interactions were observed. All three of these phase I trials
used the same gemcitabine infusion time (30 minutes) as our
trial. On the basis of the data from these previous trials that
had investigated the pharmacokinetics of gemcitabine and
paclitaxel on several different schedules in a similar patient
population, we determined that the probability of a drug-drug
interaction between nab-paclitaxel and gemcitabine was low,
and elected not to pursue a pharmacokinetic analysis of the
two drugs.
In conclusion, the maximum tolerated dose and the
dose recommended dose for phase II trials of nab-paclitaxel is
300 mg/m2 on day 1 in combination with gemcitabine 1000
mg/m2 on days 1, 8 every 21 days. In this previously treated
patient population with NSCLC, SCLC, and esophageal can-
cer, the combination of gemcitabine and nab-paclitaxel re-
vealed acceptable toxicity and encouraging preliminary evi-
dence of activity.
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